{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-127874","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2021-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.201779+00:00","generated_at":"2026-06-28T19:42:53.051537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance","bullets":["GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.","Global COVID-19 testing sales $1.9B; total organic sales growth 22.4%.","Full-year 2021 GAAP EPS guidance raised to $3.55-$3.65; adjusted $5.00-$5.10.","Board declared $0.45 quarterly dividend (payable Nov. 15, 2021); 49th consecutive annual increase.","Acquired Walk Vascular; received FDA approvals for Amplatzer Amulet, Portico TAVR, and Talisman PFO systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-127874","json":"https://secwatch.observer/filing/0001104659-21-127874.json","markdown":"https://secwatch.observer/filing/0001104659-21-127874.md","text":"https://secwatch.observer/filing/0001104659-21-127874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/0001104659-21-127874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/tm2130546d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T19:42:53.051537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}